Capravirine
Sponsors
Lexigen Pharmaceuticals, Agouron Pharmaceuticals, National Institute of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI), Pfizer
Conditions
HIV InfectionHIV InfectionsHealthyHuman Immunodeficiency Virus
Phase 1
Safety and Anti-HIV Activity of Capravirine Alone and in Combination With Other Anti-HIV Drugs
CompletedNCT00005673
Start: 2000-05-31End: 2002-05-31Target: 46Updated: 2008-03-04
Capravirine to Treat Children With HIV Infection
CompletedNCT00006519
Start: 2000-11-30End: 2004-10-31Target: 96Updated: 2006-07-11
Phase I Trial of S-1153 in Patients With HIV Infection
CompletedNCT00002214
Target: 40Updated: 2005-06-24
Phase 2
Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients
SuspendedNCT00004998
Start: 1999-11-30Target: 30Updated: 2005-06-24
Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy
CompletedNCT00004985
Start: 2000-01-31Target: 75Updated: 2005-06-24
A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments
CompletedNCT00006211
Start: 2000-02-29End: 2001-04-30Target: 350Updated: 2005-06-24
Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients
SuspendedNCT00004999
Start: 1999-08-31Target: 350Updated: 2005-06-24
Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen
CompletedNCT00051844
Start: 2002-08-31End: 2004-11-30Updated: 2011-05-10
Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens
CompletedNCT00052117
Start: 2003-01-31End: 2005-05-31Target: 300Updated: 2007-10-10